Quick on the heels of backing from a key European committee, GlaxoSmithKline ($GSK) is gearing up to launch Strimvelis, a breakthrough gene therapy for children. To lay that groundwork, the drugmaker is opening the door to radical changes in payments for the ultrapricey med to keep its cost from breaking the bank. More from FiercePharma